Related Experiment Videos
Protective DNA immunization against Chlamydia pneumoniae
C Svanholm1, L Bandholtz, E Castaños-Velez
1Microbiology and Tumorbiology Center, Department of Pathology, Karolinska Institute, Stockholm, Sweden.
Scandinavian Journal of Immunology
|March 29, 2000
Summary
DNA vaccination with heat shock protein 60 (HSP-60) protects mice against Chlamydia pneumoniae infection by inducing cell-mediated immunity, not antibodies. This approach offers a promising strategy for developing new vaccines against bacterial infections.
Area of Science:
- Immunology
- Microbiology
- Vaccinology
Background:
- Chlamydia pneumoniae is a significant human pathogen causing respiratory infections.
- Effective vaccines against C. pneumoniae are lacking.
- Heat shock protein 60 (HSP-60) is a potential target for vaccine development.
Purpose of the Study:
- To evaluate the efficacy of DNA vaccination using the HSP-60 gene of C. pneumoniae for protection against bacterial infection in mice.
- To investigate the immune mechanisms underlying DNA vaccine-induced protection.
Main Methods:
- Intranasal (i.n.) and intradermal (i.d.) DNA vaccination of C57Bl/6 mice with plasmids encoding HSP-60 (pHSP-60).
- Assessment of bacterial load in lungs, disease severity, antibody responses (IgG), and cytokine production (IFN-gamma).
- Evaluation of vaccine efficacy in knockout mice lacking specific immune components (IFN-gamma receptor, MHC class II, CD4+, CD8+ T cells).
Main Results:
- Intranasal pHSP-60 vaccination significantly reduced C. pneumoniae load and disease severity in mice.
- Protective immunity was associated with increased IFN-gamma production and T-cell responses, not specific antibodies.
- Protection was dependent on both CD4+ and CD8+ T cells, with CD4+ T cells alone potentially worsening the outcome.
- Intranasal administration of IFN-gamma gene alone also conferred protection.
Conclusions:
- DNA vaccination targeting HSP-60 via intranasal delivery is effective in protecting mice against C. pneumoniae infection.
- The protective mechanism relies on cell-mediated immunity, particularly involving interferon-gamma and T cells.
- This study highlights the potential of DNA vaccines and IFN-gamma in combating C. pneumoniae infections.